OUR TEAM

Chinmay Bagwe

Associate

Chinmay Bagwe

Associate

With the benefit of his technical knowledge and trial experience, Chinmay strives to secure favorable, client-focused results
With the benefit of his technical knowledge and trial experience, Chinmay strives to secure favorable, client-focused results

OVERVIEW

Chinmay Bagwe is an associate in the New York office focusing on intellectual property litigation, including life sciences and pharmaceutical patent litigation.  Chinmay has represented major pharmaceutical companies at trial, including Hatch-Waxman trials, and has successfully litigated cases in federal courts, including New Jersey and Delaware, and appeals before the Federal Circuit.

During law school, Chinmay interned for the Honorable Jimmie V. Reyna at the United States Court of Appeals for the Federal Circuit.  He also served as an IP Redux Leader and Editor for IDEA®: The Law Review of the Franklin Pierce Center for Intellectual Property, Vol. 59.

REPRESENTATIVE CASES

  • Supernus Pharms. Inc. v. Torrent Pharms. Ltd. et al., Nos. 21-6964, 21-14268 (D.N.J.) (Trial Victory) Represented Supernus in a Hatch-Waxman trial against Torrent Pharma concerning Supernus’s multi-million dollar anti-epileptic drug Trokendi XR®.  All of Supernus’s asserted claims across three Orange Book-listed patents were held infringed and valid.
  • Takeda Pharm. Co. Ltd. et al. v. Norwich Pharms., Inc., No. 20-8966 (D.N.J.) (Trial Victory) aff’d, 23-1374 (Fed. Cir.) Represented Takeda in a Hatch-Waxman trial and appeal against Norwich concerning Takeda’s blockbuster ADHD drug Vyvanse®.  All of Takeda’s asserted claims across nine Orange Book-listed patents were held infringed, not invalid, and enforceable.
  • Astellas US LLC et al. v. Curia Missouri Inc. et al., No. 22-0199 (D. Del.) Represented Curia in a patent litigation against plaintiffs Astellas and Gilead concerning plaintiffs’ pharmacologic stress testing agent Lexiscan®.  Plaintiffs voluntarily dismissed the case pending Curia’s case-dispositive motion to dismiss and in light of plaintiffs’ defeat at trial and on appeal in a related case: Astellas US LLC et al. v. Hospira, Inc., No. 18-1675 (D. Del.) (finding that Curia’s API and manufacturing process do not infringe the asserted patent claims) aff’d, 22-1878 (Fed. Cir.).
  • AbbVie Endocrine Inc. v. Takeda Pharm. Co. Ltd., No. 20-0953 (Del. Ch.) (Injunction Trial Victory) Represented Takeda in the injunction phase of a trial arising from a breach of contract dispute against AbbVie concerning AbbVie’s endometriosis and prostate cancer treatment Lupron Depot®.  AbbVie’s request for expedited injunctive relief was denied.
VIEW ALL

EDUCATION

  • UNH Franklin Pierce School of Law, J.D., IP Cert., 2019
  • NMIMS Institute of Intellectual Property Studies, IP Cert., 2016
  • University of Mumbai, M.S., Biotech., 2015
VIEW ALL

AWARDS

  • Atlas Award, Leadership Council on Legal Diversity, Pathfinder, 2023
  • Excellence in Intellectual Property, UNH Franklin Pierce School of Law, 2019
VIEW ALL

BAR ADMISSIONS

  • State Bar of New York
  • U.S. Court of Appeals for the Federal Circuit
  • Southern District of New York
  • Eastern District of New York
VIEW ALL

MEMBERSHIPS

  • New York City Bar Association
  • Federal Bar Association
  • Leadership Council on Legal Diversity
  • Asian American Bar Association of New York
VIEW ALL

LANGUAGES

  • Hindi
  • Marathi

CONTACT

LOCATION

New York City
745 Fifth Avenue, 10th Floor, 
New York, NY 10151
745 Fifth Avenue, 10th Floor, New York, NY 10151